

# Gary Cook

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6574373/publications.pdf>

Version: 2024-02-01

211  
papers

11,966  
citations

34016

52  
h-index

30010

103  
g-index

215  
all docs

215  
docs citations

215  
times ranked

13555  
citing authors

#	ARTICLE	IF	CITATIONS
1	Imaging of Bone Metastases in Breast Cancer. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 531-541.	2.5	3
2	Radiomic Analysis of Tumour Heterogeneity Using MRI in Head and Neck Cancer Following Chemoradiotherapy: A Feasibility Study. <i>Frontiers in Oncology</i> , 2022, 12, 784693.	1.3	2
3	Radiomic assessment of oesophageal adenocarcinoma: a critical review of 18F-FDG PET/CT, PET/MRI and CT. <i>Insights Into Imaging</i> , 2022, 13, .	1.6	4
4	<sup>18</sup> F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer. <i>Radiology</i> , 2022, 304, 246-264.	3.6	14
5	Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2558-2565.	3.3	13
6	18F-FDG PET-CT and 18F-NaF in Treatment Response Evaluation: Bone Metastases and Bone Tumours. , 2021, , 403-417.		0
7	A Multi-Channel Uncertainty-Aware Multi-Resolution Network for MR to CT Synthesis. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 1667.	1.3	7
8	Systematic review of research design and reporting of imaging studies applying convolutional neural networks for radiological cancer diagnosis. <i>European Radiology</i> , 2021, 31, 7969-7983.	2.3	14
9	Correlations between DWâ€MRI and 18 Fâ€FDG PET / CT parameters in head and neck squamous cell carcinoma following definitive chemoâ€radiotherapy. <i>Cancer Reports</i> , 2021, 4, e1360.	0.6	4
10	Standardisation of conventional and advanced iterative reconstruction methods for Gallium-68 multi-centre PET-CT trials. <i>EJNMMI Physics</i> , 2021, 8, 52.	1.3	8
11	Optimisation of CT protocols in PET-CT across different scanner models using different automatic exposure control methods and iterative reconstruction algorithms. <i>EJNMMI Physics</i> , 2021, 8, 58.	1.3	3
12	An overview of nuclear medicine research in the UK and the landscape for clinical adoption. <i>Nuclear Medicine Communications</i> , 2021, Publish Ahead of Print, 1301-1312.	0.5	0
13	Diagnostic Accuracy of FEC-PET/CT, FDG-PET/CT, and Diffusion-Weighted MRI in Detection of Nodal Metastases in Surgically Treated Endometrial and Cervical Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 6457-6466.	3.2	11
14	Temporospatial heterogeneity of acquired resistance mechanisms in EGFR-mutant lung adenocarcinoma: A case of concurrent EGFR mutation and small cell transformation. <i>Current Problems in Cancer Case Reports</i> , 2021, 4, 100106.	0.1	2
15	Preclinical development and characterisation of Tc-NM-01 for SPECT/CT imaging of human PD-L1. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 11, 154-166.	1.0	1
16	[18F] Sodium Fluoride PET Kinetic Parameters in Bone Imaging. <i>Tomography</i> , 2021, 7, 843-854.	0.8	8
17	Sparse Regression in Cancer Genomics: Comparing Variable Selection and Predictions in Real World Data. <i>Cancer Informatics</i> , 2021, 20, 117693512110562.	0.9	2
18	Initial experience in staging primary oesophageal/gastro-oesophageal cancer with 18F-FDG PET/MRI. <i>European Journal of Hybrid Imaging</i> , 2021, 5, 23.	0.6	7

#	ARTICLE	IF	CITATIONS
19	Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 16-17.	3.3	1
20	Staging FDG PET-CT changes management in patients with gastric adenocarcinoma who are eligible for radical treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 759-767.	3.3	28
21	Radiomic analysis for response assessment in advanced head and neck cancers, a distant dream or an inevitable reality? A systematic review of the current level of evidence. <i>British Journal of Radiology</i> , 2020, 93, 20190496.	1.0	19
22	Heterogeneity in tumours: Validating the use of radiomic features on 18F-FDG PET/CT scans of lung cancer patients as a prognostic tool. <i>Radiotherapy and Oncology</i> , 2020, 144, 72-78.	0.3	35
23	The management impact of 68gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (68Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 674-686.	3.3	29
24	The Role of PET-CT Imaging in Prostate Cancer. <i>Seminars in Ultrasound, CT and MRI</i> , 2020, 41, 373-391.	0.7	1
25	A Role for FDG PET Radiomics in Personalized Medicine?. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 532-540.	2.5	12
26	The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. <i>Radiology</i> , 2020, 295, 328-338.	3.6	1,869
27	Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2971-2980.	0.8	61
28	Introduction to Radiomics. <i>Journal of Nuclear Medicine</i> , 2020, 61, 488-495.	2.8	673
29	Effect of 18F-Fluciclovine Positron Emission Tomography on the Management of Patients With Recurrence of Prostate Cancer: Results From the FALCON Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 316-324.	0.4	50
30	Imaging with radiolabelled bisphosphonates. <i>Bone</i> , 2020, 137, 115372.	1.4	9
31	Molecular Imaging of Bone Metastases and Their Response to Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 799-806.	2.8	37
32	Nuclear Medicine Imaging Techniques of the Musculoskeletal System. , 2020, , 381-430.		1
33	Is Response Assessment of Breast Cancer Bone Metastases Better with Measurement of <sup>18</sup> F-Fluoride Metabolic Flux Than with Measurement of <sup>18</sup> F-Fluoride PET/CT SUV?. <i>Journal of Nuclear Medicine</i> , 2019, 60, 322-327.	2.8	23
34	Radiomics in esophageal and gastric cancer. <i>Abdominal Radiology</i> , 2019, 44, 2048-2058.	1.0	59
35	PSMA PET/CT imaging for primary staging of intermediate and high-risk prostate cancer. <i>BJU International</i> , 2019, 124, 357-358.	1.3	3
36	Assessment of the Spatial Heterogeneity of Breast Cancers: Associations Between Computed Tomography and Immunohistochemistry. <i>Biomarkers in Cancer</i> , 2019, 11, 1179299X1985151.	3.6	4

#	ARTICLE	IF	CITATIONS
37	Non-invasive classification of non-small cell lung cancer: a comparison between random forest models utilising radiomic and semantic features. <i>British Journal of Radiology</i> , 2019, 92, 20190159.	1.0	32
38	What can artificial intelligence teach us about the molecular mechanisms underlying disease?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2715-2721.	3.3	15
39	Loco-regional staging of malignant pleural mesothelioma by integrated 18F-FDG PET/MRI. <i>European Journal of Radiology</i> , 2019, 115, 46-52.	1.2	19
40	Adaptive statistical iterative reconstruction (ASIR) affects CT radiomics quantification in primary colorectal cancer. <i>European Radiology</i> , 2019, 29, 5227-5235.	2.3	27
41	Exploratory radiomic features from integrated 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging are associated with contemporaneous metastases in oesophageal/gastroesophageal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1478-1484.	3.3	17
42	Early Phase I Study of a <sup>99m</sup> Tc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1213-1220.	2.8	111
43	MRI heterogeneity analysis for prediction of recurrence and disease free survival in anal cancer. <i>Radiotherapy and Oncology</i> , 2019, 134, 119-126.	0.3	15
44	Localising occult prostate cancer metastasis with advanced imaging techniques (LOCATE trial): a prospective cohort, observational diagnostic accuracy trial investigating whole-body magnetic resonance imaging in radio-recurrent prostate cancer. <i>BMC Medical Imaging</i> , 2019, 19, 90.	1.4	9
45	UK guidelines on 18F-fluciclovine PET/CT in prostate cancer imaging. <i>Nuclear Medicine Communications</i> , 2019, 40, 662-674.	0.5	6
46	Measurement of 18F-FDG PET tumor heterogeneity improves early assessment of response to bevacizumab compared with the standard size and uptake metrics in a colorectal cancer model. <i>Nuclear Medicine Communications</i> , 2019, 40, 611-617.	0.5	7
47	Discovery of pre-therapy 2-deoxy-2-18F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 455-466.	3.3	59
48	Does Measurement of First-Order and Heterogeneity Parameters Improve Response Assessment of Bone Metastases in Breast Cancer Compared to SUVmax in [18F]fluoride and [18F]FDG PET?. <i>Molecular Imaging and Biology</i> , 2019, 21, 781-789.	1.3	11
49	Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [18F]fluorodeoxyglucose and [18F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 821-830.	3.3	31
50	The role of new PET tracers for lung cancer. <i>Minerva Pneumologica</i> , 2019, 58, .	1.6	0
51	Reply: Relevance of Measurement Uncertainty for Quantitative Response Assessment of Breast Cancer Bone Metastases with <sup>18</sup> F-Fluoride. <i>Journal of Nuclear Medicine</i> , 2019, 60, 569.1-569.	2.8	4
52	Functional and Hybrid Imaging of Bone Metastases. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 961-972.	3.1	18
53	Imaging $\alpha$ v $\beta$ 3 integrin expression in skeletal metastases with <sup>99m</sup> Tc-maraciclalide single-photon emission computed tomography: detection and therapy response assessment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 898-903.	3.3	9
54	Challenges and Promises of PET Radiomics. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1083-1089.	0.4	121

#	ARTICLE	IF	CITATIONS
55	Imaging of Tumour Heterogeneity: Functional MR Techniques in Oncology. , 2018, , 131-150.		0
56	Comparison of whole body magnetic resonance imaging (WBMRI) to whole body computed tomography (WBCT) or 18 F-fluorodeoxyglucose positron emission tomography/CT ( 18 F-FDG PET/CT) in patients with myeloma: Systematic review of diagnostic performance. Critical Reviews in Oncology/Hematology, 2018, 124, 66-72.	2.0	43
57	Thyroid Paraganglioma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 416-423.	0.6	17
58	UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer. British Journal of Radiology, 2018, 91, 20170577.	1.0	70
59	Investigating the histopathologic correlates of 18F-FDG PET heterogeneity in non-small-cell lung cancer. Nuclear Medicine Communications, 2018, 39, 1197-1206.	0.5	13
60	Multitracer Guided PET Image Reconstruction. IEEE Transactions on Radiation and Plasma Medical Sciences, 2018, 2, 499-509.	2.7	13
61	Measuring validity of response assessment in bone predominant metastatic breast cancer based on clinico-radiological evaluation: An Inter-observer study.. Journal of Clinical Oncology, 2018, 36, e13055-e13055.	0.8	1
62	One Coin, No Need to Flip: Shared PET Targets in Cancer and Coronary Artery Disease. American Journal of Roentgenology, 2017, 208, 434-445.	1.0	0
63	<sup>18</sup> F-Tetrafluoroborate, a PET Probe for Imaging Sodium/Iodide Symporter Expression: Whole-Body Biodistribution, Safety, and Radiation Dosimetry in Thyroid Cancer Patients. Journal of Nuclear Medicine, 2017, 58, 1666-1671.	2.8	55
64	Primary Rectal Cancer: Repeatability of Global and Local-Regional MR Imaging Texture Features. Radiology, 2017, 284, 552-561.	3.6	66
65	Magnetic Resonance Imaging (MRI) of Intratumoral Voxel Heterogeneity as a Potential Response Biomarker: Assessment in a HER2+ Esophageal Adenocarcinoma Xenograft Following Trastuzumab and/or Cisplatin Therapy. Translational Oncology, 2017, 10, 459-467.	1.7	2
66	Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated <sup>18</sup> F-Fluorodeoxyglucose ( <sup>18</sup> F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study. BMC Cancer, 2017, 17, 392.	1.1	14
67	The effect of post-injection <sup>18</sup> F-FDG PET scanning time on texture analysis of peripheral nerve sheath tumours in neurofibromatosis-1. EJNMMI Research, 2017, 7, 35.	1.1	16
68	Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of <sup>18</sup> F-FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1845-1852.	3.3	21
69	Intraoperative Assessment of Tumor Resection Margins in Breast-Conserving Surgery Using <sup>18</sup> F-FDG Cerenkov Luminescence Imaging: A First-in-Human Feasibility Study. Journal of Nuclear Medicine, 2017, 58, 891-898.	2.8	91
70	New horizons in multimodality molecular imaging and novel radiotracers. Clinical Medicine, 2017, 17, 444-448.	0.8	3
71	Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology, 2017, 14, 169-186.	12.5	792
72	[ <sup>18</sup> F]-Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis, Treatment Stratification, and Monitoring of Patients with Retroperitoneal Fibrosis: A Prospective Clinical Study. European Urology, 2017, 71, 926-933.	0.9	34

#	ARTICLE	IF	CITATIONS
73	Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer. BMC Cancer, 2017, 17, 494.	1.1	17
74	The effects of segmentation algorithms on the measurement of 18F-FDG PET texture parameters in non-small cell lung cancer. EJNMMI Research, 2017, 7, 60.	1.1	50
75	Guided Image Reconstruction for Multi-Tracer PET. , 2017, , .		2
76	Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1â€“Deficient Thoracic Cancers. Journal of Clinical Oncology, 2017, 35, 1778-1785.	0.8	96
77	Clinical Applications of PET/CT in Oncology. , 2017, , 429-450.		6
78	Challenges in imaging assessment following liver stereotactic body radiotherapy: pitfalls to avoid in clinical practice. Chinese Clinical Oncology, 2017, 6, S11-S11.	0.4	10
79	FDG PET-CT: Need for vigilance in patients treated with bleomycin. Indian Journal of Nuclear Medicine, 2017, 32, 122.	0.1	12
80	Physiologic and Molecular Basis of PET in Cancer Imaging. , 2017, , 399-427.		2
81	An Incidental Renal Oncocytoma: 18F-Choline PET/MRI. Diagnostics, 2016, 6, 14.	1.3	0
82	Sentinel Lymph Node Biopsy in Pelvic Tumors. Clinical Nuclear Medicine, 2016, 41, e288-e293.	0.7	9
83	Sentinel lymph node biopsy in breast cancer. Nuclear Medicine Communications, 2016, 37, 570-576.	0.5	18
84	Molecular and Functional Imaging of Bone Metastases in Breast and Prostate Cancers. Clinical Nuclear Medicine, 2016, 41, e44-e50.	0.7	30
85	PET Imaging of Skeletal Metastases and Its Role in Personalizing Further Management. PET Clinics, 2016, 11, 305-318.	1.5	12
86	Multi-technique imaging of bone metastases: spotlight on PET-CT. Clinical Radiology, 2016, 71, 620-631.	0.5	22
87	A Role for Tumor Volume Assessment in Resectable Esophageal Cancer. Annals of Surgical Oncology, 2016, 23, 3063-3070.	0.7	15
88	Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology. Clinical and Translational Imaging, 2016, 4, 439-447.	1.1	56
89	Molecular Imaging in the Management of Adrenocortical Cancer. Clinical Nuclear Medicine, 2016, 41, e368-e382.	0.7	23
90	Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging. Oncologist, 2016, 21, 1502-1508.	1.9	16

#	ARTICLE	IF	CITATIONS
91	Is there a role for PET/CT in the evaluation of primary and secondary hyperparathyroidism?. Nuclear Medicine Communications, 2016, 37, 1-2.	0.5	7
92	Imaging Heterogeneity in Lung Cancer: Techniques, Applications, and Challenges. American Journal of Roentgenology, 2016, 207, 534-543.	1.0	121
93	Imaging Bone Metastases in Breast Cancer: Staging and Response Assessment. Journal of Nuclear Medicine, 2016, 57, 27S-33S.	2.8	84
94	The role of new PET tracers for lung cancer. Lung Cancer, 2016, 94, 7-14.	0.9	47
95	Positron Emission Tomography/Magnetic Resonance Imaging of Gastrointestinal Cancers. Seminars in Ultrasound, CT and MRI, 2016, 37, 352-357.	0.7	4
96	Clinical significance of hypoxia in nasopharyngeal carcinoma with a focus on existing and novel hypoxia molecular imaging. Chinese Clinical Oncology, 2016, 5, 24-24.	0.4	4
97	Pathological heterogeneity after trastuzumab and combination chemotherapy in HER2+ gastroesophageal adenocarcinoma xenograft.. Journal of Clinical Oncology, 2016, 34, 42-42.	0.8	0
98	What is the role of radionuclide sentinel lymph node biopsy and dissection in papillary thyroid cancer?. Nuclear Medicine Communications, 2015, 36, 969-970.	0.5	3
99	The Role of Routine Clinical Pretreatment 18F-FDG PET/CT in Predicting Outcome of Colorectal Liver Metastasis. Clinical Nuclear Medicine, 2015, 40, e259-e264.	0.7	16
100	The role of 18F-FDG PET/CT in the management of testicular cancers. Nuclear Medicine Communications, 2015, 36, 702-708.	0.5	40
101	Monthly ibandronate versus weekly risedronate treatment for low bone mineral density in stable renal transplant patients. Nuclear Medicine Communications, 2015, 36, 815-818.	0.5	10
102	Imaging Tumor Response and Tumoral Heterogeneity in Non-“Small Cell Lung Cancer Treated With Antiangiogenic Therapy. Journal of Thoracic Imaging, 2015, 30, 300-307.	0.8	12
103	PET/MRI in Oncological Imaging: State of the Art. Diagnostics, 2015, 5, 333-357.	1.3	37
104	Predicting Response to Neoadjuvant Chemotherapy with PET Imaging Using Convolutional Neural Networks. PLoS ONE, 2015, 10, e0137036.	1.1	139
105	The precision of textural analysis in 18F-FDG-PET scans of oesophageal cancer. European Radiology, 2015, 25, 2805-2812.	2.3	66
106	Non-“Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of <sup>18</sup> F-FDG Uptake at PET-“Association with Treatment Response and Prognosis. Radiology, 2015, 276, 883-893.	3.6	147
107	Molecular imaging of hypoxia in non-small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 956-976.	3.3	50
108	Multimodal Partial-Volume Correction: Application to <sup>18</sup> F-Fluoride PET/CT Bone Metastases Studies. Journal of Nuclear Medicine, 2015, 56, 1408-1414.	2.8	10

#	ARTICLE	IF	CITATIONS
109	Bench to bedside molecular functional imaging in translational cancer medicine: to image or to imagine?. <i>Clinical Radiology</i> , 2015, 70, 1060-1082.	0.5	54
110	Texture analysis of 125I-A5B7 anti-CEA antibody SPECT differentiates metastatic colorectal cancer model phenotypes and anti-vascular therapy response. <i>British Journal of Cancer</i> , 2015, 112, 1882-1887.	2.9	19
111	Challenges for imaging and therapy of musculoskeletal tumours. <i>Clinical and Translational Imaging</i> , 2015, 3, 79-81.	1.1	0
112	Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. <i>Insights Into Imaging</i> , 2015, 6, 489-497.	1.6	149
113	Assessment of changes in tumor heterogeneity following neoadjuvant chemotherapy in primary esophageal cancer. <i>Ecological Management and Restoration</i> , 2015, 28, 172-179.	0.2	77
114	Multiparametric MRI assessment during cisplatin and trastuzumab therapy in esophageal adenocarcinoma xenografts.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15108-e15108.	0.8	0
115	Phase I study of ADI-PEG 20 in combination with pemetrexed and cisplatin (TRAP) in patients with ASS1-deficient mesothelioma and non-squamous lung cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS2612-TPS2612.	0.8	0
116	Bone metastases in prostate cancer: which scan?. <i>BJU International</i> , 2014, 114, 792-793.	1.3	0
117	18F-FDG PET Rarely Provides Additional Information to 11C-Methionine PET Imaging in Hyperparathyroidism. <i>Clinical Nuclear Medicine</i> , 2014, 39, 237-242.	0.7	20
118	Imaging Assessment of Lung Tumor Angiogenesis: Insights and Innovations. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014, 35, 112-128.	0.8	2
119	The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 276-282.	3.3	59
120	Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. <i>European Radiology</i> , 2014, 24, 998-1005.	2.3	181
121	Radiomics in PET: principles and applications. <i>Clinical and Translational Imaging</i> , 2014, 2, 269-276.	1.1	103
122	Assessment of tumoral heterogeneity in NSCLC treated with bevacizumab: A prospective study.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19124-e19124.	0.8	0
123	Imaging Breast Cancer Bone Metastases: Current Status and Future Directions. <i>Seminars in Nuclear Medicine</i> , 2013, 43, 317-323.	2.5	30
124	18F-FDG PET/CT in HIV-related central nervous system pathology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1420-1427.	3.3	29
125	The isotope bone scan: we can do better. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1139-1140.	3.3	9
126	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R92.	2.2	320



#	ARTICLE	IF	CITATIONS
127	Changes in functional imaging parameters following induction chemotherapy have important implications for individualised patient-based treatment regimens for advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2013, 106, 112-117.	0.3	39
128	Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 133-140.	3.3	395
129	Combined 18F-Fluoride and 18F-FDG PET/CT Scanning for Evaluation of Malignancy: Results of an International Multicenter Trial. <i>Journal of Nuclear Medicine</i> , 2013, 54, 173-175.	2.8	6
130	Are Pretreatment <sup>18</sup> F-FDG PET Tumor Textural Features in Non-Small Cell Lung Cancer Associated with Response and Survival After Chemoradiotherapy?. <i>Journal of Nuclear Medicine</i> , 2013, 54, 19-26.	2.8	361
131	Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication. <i>Nuclear Medicine Communications</i> , 2013, 34, 1075-1083.	0.5	14
132	Influence of three reconstruction algorithms on the estimation of the standardized uptake value in <sup>18</sup> F-fluoride PET. , 2013, , .		1
133	Fluorodeoxyglucose positron emission tomography ( <sup>18</sup> F-FDG PET)/computed tomography ( <sup>18</sup> F-FDG PET/CT) in bladder cancer. <i>BJU International</i> , 2013, 112, 709-709.	1.3	1
134	Can 18F-FDG PET/CT Reliably Assess Response to Primary Treatment of Head and Neck Cancer?. <i>Clinical Nuclear Medicine</i> , 2013, 38, 263-265.	0.7	21
135	Comparison of six quantitative methods for the measurement of bone turnover at the hip and lumbar spine using 18F-fluoride PET-CT. <i>Nuclear Medicine Communications</i> , 2012, 33, 597-606.	0.5	18
136	Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice?. <i>Insights Into Imaging</i> , 2012, 3, 573-589.	1.6	738
137	Functional imaging techniques in hepatocellular carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1070-1079.	3.3	16
138	Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials. <i>European Radiology</i> , 2012, 22, 1465-1478.	2.3	17
139	Elevated CEA level in the asymptomatic patient with normal conventional imaging: How useful is PET-CT for the detection of colorectal cancer recurrence?. <i>Journal of Clinical Oncology</i> , 2012, 30, 400-400.	0.8	1
140	Lung, Thyroid, Renal Cancer, Myeloma and Neuroendocrine Cancers: Role of Planar, SPECT and PET in Imaging Bone Metastases. , 2012, , 691-715.		0
141	Bone Scintigraphy in Metabolic Bone Disease. , 2012, , 435-444.		0
142	Primary Bone and Soft Tissue Tumours: Role of 18FDG PET. , 2012, , 777-786.		0
143	Conventional Nuclear Medicine and Hybrid Imaging in Monitoring the Treatment of Skeletal Malignancy. , 2012, , 717-734.		0
144	Corrigendum to "Randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema after radiotherapy for cancer" [Radiother Oncol 97 (2010) 101-107]. <i>Radiotherapy and Oncology</i> , 2011, 98, 285.	0.3	0

#	ARTICLE	IF	CITATIONS
145	Validation of image-derived arterial input functions at the femoral artery using 18F-fluoride positron emission tomography. Nuclear Medicine Communications, 2011, 32, 808-817.	0.5	18
146	Validation of new image-derived arterial input functions at the aorta using 18F-fluoride positron emission tomography. Nuclear Medicine Communications, 2011, 32, 486-495.	0.5	18
147	Positron emission tomography computed tomography in oncology. British Journal of Hospital Medicine (London, England: 2005), 2011, 72, 631-637.	0.2	5
148	18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI Research, 2011, 1, 4.	1.1	99
149	The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 7-13.	3.3	54
150	The CT flare response of metastatic bone disease in prostate cancer. Acta Radiologica, 2011, 52, 557-561.	0.5	55
151	PET-CT of Esophageal Cancer. , 2011, , 181-191.		0
152	Differences in Skeletal Kinetics Between Vertebral and Humeral Bone Measured by 18F-Fluoride Positron Emission Tomography in Postmenopausal Women. Journal of Bone and Mineral Research, 2010, 15, 763-769.	3.1	61
153	Is FDG-PET suitable for evaluating neoadjuvant therapy in non-small cell lung cancer? Evidence with systematic review of the literature. Journal of Surgical Oncology, 2010, 101, 486-494.	0.8	33
154	Review article: PET and PET/CT imaging of skeletal metastases. Cancer Imaging, 2010, 10, 153-160.	1.2	39
155	18F-Fluoride PET and PET/CT Imaging of Skeletal Metastases. PET Clinics, 2010, 5, 275-280.	1.5	1
156	Randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema after radiotherapy for cancer. Radiotherapy and Oncology, 2010, 97, 101-107.	0.3	42
157	Miscellaneous Indications in Bone Scintigraphy: Metabolic Bone Diseases and Malignant Bone Tumors. Seminars in Nuclear Medicine, 2010, 40, 52-61.	2.5	23
158	Skeletal metastases: what is the future role for nuclear medicine?. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1803-1806.	3.3	6
159	Differences in regional bone perfusion and turnover between lumbar spine and distal humerus: 18F-fluoride PET study of treatment-naïve and treated postmenopausal women. Bone, 2009, 45, 942-948.	1.4	44
160	Effective avoidance of a functional spect-perfused lung using intensity modulated radiotherapy (IMRT) for non-small cell lung cancer (NSCLC): An update of a planning study. Radiotherapy and Oncology, 2009, 91, 349-352.	0.3	43
161	Miscellaneous Cancers (Lung, Thyroid, Renal Cancer, Myeloma, and Neuroendocrine Tumors): Role of SPECT and PET in Imaging Bone Metastases. Seminars in Nuclear Medicine, 2009, 39, 416-430.	2.5	66
162	Patterns, Variants, Artifacts, and Pitfalls in Conventional Radionuclide Bone Imaging and SPECT/CT. Seminars in Nuclear Medicine, 2009, 39, 380-395.	2.5	99

#	ARTICLE	IF	CITATIONS
163	18F-Fluorodeoxyglucose Positron Emission Tomography for the Evaluation of Neoadjuvant Therapy Response in Esophageal Cancer. <i>Annals of Surgery</i> , 2009, 250, 247-254.	2.1	59
164	Perioperative use of radioisotopes. <i>Surgery</i> , 2008, 26, 261-268.	0.1	0
165	Ensuring the right PET scan for the right patient. <i>Lung Cancer</i> , 2008, 59, 48-56.	0.9	13
166	Follicular Thyroid Carcinoma Metastasis to the Esophagus Detected by 18FDG PET/CT. <i>Thyroid</i> , 2008, 18, 267-271.	2.4	12
167	Evaluation of the role of <sup>18</sup> F-FDG-PET/CT in radiotherapy target definition in patients with head and neck cancer. <i>Acta Oncologica</i> , 2008, 47, 1229-1236.	0.8	28
168	Long-Term Precision of <sup>18</sup> F-Fluoride PET Skeletal Kinetic Studies in the Assessment of Bone Metabolism. <i>Journal of Nuclear Medicine</i> , 2008, 49, 700-707.	2.8	62
169	MRI or Bone Scan or Both for Staging of Prostate Cancer?. <i>Journal of Clinical Oncology</i> , 2007, 25, 5837-5838.	0.8	15
170	A potential to reduce pulmonary toxicity: The use of perfusion SPECT with IMRT for functional lung avoidance in radiotherapy of non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2007, 83, 156-162.	0.3	76
171	The Relationship Between Regional Bone Turnover Measured Using 18F-fluoride Positron Emission Tomography and Changes in BMD Is Equivalent to That Seen for Biochemical Markers of Bone Turnover. <i>Journal of Clinical Densitometry</i> , 2007, 10, 46-54.	0.5	30
172	Unusual presentation of metastatic adenocarcinoma. <i>World Journal of Surgical Oncology</i> , 2007, 5, 116.	0.8	2
173	Case report: PET/CT, a cautionary tale. <i>BMC Cancer</i> , 2007, 7, 147.	1.1	2
174	Preparation and Use of <sup>131</sup> I Magic Gel as a Dosimeter for Targeted Radionuclide Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2006, 21, 427-436.	0.7	10
175	Neuron-specific enolase expression in multiple myeloma. <i>Lancet Oncology</i> , 2006, 7, 960.	5.1	3
176	Radioisotope and PET Imaging of Bone Metastases. , 2006, , 77-90.		0
177	Positron emission tomography in oncology. <i>British Medical Bulletin</i> , 2006, 79-80, 171-186.	2.7	13
178	Artifacts and Normal Variants in Whole-Body PET and PET/CT Imaging. , 2006, , 63-77.		1
179	PET Imaging of the Skeleton. , 2006, , 317-335.		2
180	Clinical PET Imaging. , 2005, , 347-364.		0

#	ARTICLE	IF	CITATIONS
181	Metastatic Thyroid Carcinoma Causing Superior Vena Caval Obstruction Diagnosed on I-131 Scan. <i>Clinical Nuclear Medicine</i> , 2005, 30, 548-549.	0.7	3
182	Artefacts and Normal Variants in Whole-Body PET and PET/CT Imaging. , 2005, , 281-293.		2
183	The incorporation of SPECT functional lung imaging into inverse radiotherapy planning for non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2005, 77, 271-277.	0.3	100
184	Positron emission tomography for target volume definition in the treatment of non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2005, 77, 1-4.	0.3	54
185	Positron emission tomography and bone metastases. <i>Seminars in Nuclear Medicine</i> , 2005, 35, 135-142.	2.5	218
186	Diagnostic 131I whole body scanning after thyroidectomy and ablation for differentiated thyroid cancer. <i>European Journal of Endocrinology</i> , 2004, 150, 649-653.	1.9	13
187	What's new in â€¦ Positron emission tomography. <i>Medicine</i> , 2004, 32, 1-4.	0.2	0
188	Dissociation Between Global Markers of Bone Formation and Direct Measurement of Spinal Bone Formation in Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 1797-1804.	3.1	67
189	Issues undermining provision of diagnostic imaging in the UK. <i>Lancet Oncology</i> , The, 2004, 5, 467-468.	5.1	1
190	Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. <i>Seminars in Nuclear Medicine</i> , 2004, 34, 122-133.	2.5	241
191	Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma. <i>Radiotherapy and Oncology</i> , 2004, 73, 277-283.	0.3	63
192	A Prospective Study of Risedronate on Regional Bone Metabolism and Blood Flow at the Lumbar Spine Measured by 18 F-Fluoride Positron Emission Tomography. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 2215-2222.	3.1	82
193	New Horizons in Oncologic Imaging. <i>New England Journal of Medicine</i> , 2003, 348, 2487-2488.	13.9	45
194	Positron-emission Tomography Used to Diagnose Tuberculosis in a Renal Transplant Patient. <i>American Journal of Transplantation</i> , 2002, 2, 105-107.	2.6	9
195	Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. <i>Seminars in Nuclear Medicine</i> , 2001, 31, 28-49.	2.5	254
196	The role of positron emission tomography in skeletal disease. <i>Seminars in Nuclear Medicine</i> , 2001, 31, 50-61.	2.5	94
197	The role of nuclear medicine in monitoring treatment in skeletal malignancy. <i>Seminars in Nuclear Medicine</i> , 2001, 31, 206-211.	2.5	69
198	Dual-modality imaging. <i>European Radiology</i> , 2001, 11, 1857-1858.	2.3	19

#	ARTICLE	IF	CITATIONS
199	The role of positron emission tomography in the management of bone metastases. <i>Cancer</i> , 2000, 88, 2927-2933.	2.0	137
200	Renovascular Disease. <i>Clinical Radiology</i> , 2000, 55, 1-12.	0.5	18
201	Non-invasive assessment of skeletal kinetics using fluorine-18 fluoride positron emission tomography: evaluation of image and population-derived arterial input functions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 1424-1429.	3.3	63
202	Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 1363-1378.	3.3	228
203	Skeletal metastases from breast cancer: Imaging with nuclear medicine. <i>Seminars in Nuclear Medicine</i> , 1999, 29, 69-79.	2.5	58
204	An Unusual Pathologic Fracture in Metastatic Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 1998, 23, 554.	0.7	0
205	Back pain: Can we make a contribution?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 363-367.	2.2	6
206	Successful repeat transcatheter ablation of a mediastinal parathyroid adenoma 6 years after alcohol embolization. <i>CardioVascular and Interventional Radiology</i> , 1997, 20, 314-316.	0.9	7
207	Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: Potential for error in interpretation. <i>Seminars in Nuclear Medicine</i> , 1996, 26, 308-314.	2.5	358
208	Lateral collateral ligament tear of the knee: appearances on bone scintigraphy with single-photon emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 720-722.	2.2	14
209	Comparative assessment of small intestinal and colonic permeability in HIV-infected homosexual men. <i>Aids</i> , 1995, 9, 1009-1016.	1.0	19
210	An evaluation of Technegas as a ventilation agent compared with krypton-81 m in the scintigraphic diagnosis of pulmonary embolism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1992, 19, 770-4.	2.2	29
211	Positron Emmision Tomography in Lung Cancer. , 0, , 84-98.		0